Salarius Pharmaceuticals, Inc. — Director's Dealing 2021

May 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Salarius Pharmaceuticals, Inc. (SLRX)
CIK: 0001615219
Period of Report: 2021-05-03

Reporting Person: Rosenblum Mark J (Exec VP Finance, CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-03	Common Stock	A	9563	$0.567	Acquired	26286	Direct

Footnotes

F1: The reporting person voluntarily agreed to receive a percentage of his base salary in issuer shares and receive these shares in lieu of net cash compensation. Shares are purchased at a price determined pursuant to the issuer's Employee Stock Purchase Plan.